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Letter to the Editor

Menopause in Brazilian women with sickle cell
anemia with and without hydroxyurea therapy
Introduction
Women with sickle cell anemia (SCA) require special attention
for myriad obstetric and gynecologic issues associated with
this complex hematologic disorder. These affect all aspects of
female life from menarche through menopause. Information
regarding obstetric and gynecologic complications of sickle
cell disease (SCD), with a few exceptions, is based primarily on
observational, anecdotal, retrospective, or cohort studies that
may not reflect current aspects of obstetric care.1 Similarly,
there are no recent reports about menopause (also known as
climacteric) in women with SCA. The fact that life expectancy
of women with SCA was determined to be 46–48 years2 delayed
studies about menopause. The recent improved survival of
patients with SCA resulted in women reaching the age that
is usually associated with the onset of menopause. The purpose of this letter is to determine if the onset of menopause
is early or late in women with SCA and if hydroxyurea affects
the onset of menopause.

Methods
Fifteen Brazilian women with sickle cell anemia (SCA) who
were followed in the sickle cell program of the Department of
Hematology, Instituto de Hematologia Arthur de Siqueira Cavalcanti (HEMORIO), Rio de Janeiro, RJ, Brazil were included in
this study. Only women who had menopause for the previous
two years were enrolled in the study. Menopause was defined
by the cessation of menstruation for 12 consecutive months.3
This was a questionnaire study. Personal interviews were conducted with each patient. Questions included age of menarche
and menopause, intake of hydroxyurea (HU), frequency of
painful episodes before and after menopause and the effect
of menopause on hot flashes, insomnia, depression, anxiety, vaginal dryness and decreased libido.4 Follicle-stimulating
hormone (FSH) and estradiol were not measured. The dose of
HU was 15 mg/kg/day by mouth for the patients taking it.
Mean and standard deviation were calculated via basic
statistics in Systat 13. The continuous variables studied had

symmetric distribution and analysis of the data used the
paired t test to compare the variables mentioned. We also
compared variables using the Friedman Test. Significance was
based on a p value equal to 0.05 or less.
Laboratory data from medical records were also obtained
retrospectively. All these parameters were identified two years
before the onset of menopause and two years after its onset.
The study was approved by the local institutional review
board.

Results
Table 1 lists the age of the women enrolled in the study at
menarche and menopause and whether they were on HU or
not. The age of menarche in the general population is about 13
years and about 15 years in SCA.1 Since HU was not available
when the patients studied were in their teens, its effect on the
age of menarche is not known to date. However, HU lowers the
age of menopause significantly: (44.4 vs 49.3, p = 0.03).
The clinical observations by the women studied after the
onset of menopause are also summarized in Table 1. The
majority of the women (80%) indicated that the severity of
sickle cell pain decreased after menopause. This salutary
effect was counter-balanced by the signs and symptoms of
menopause, most notably hot flashes, insomnia, depression
and anxiety.
Supplementary Table 1 compare pertinent lab data before
and after menopause in patients taking HU or not respectively
and in all patients. The change in RBC indices and Hb F are
obviously due to HU.

Discussion
Early obstetric reports stressed the decreased incidence of
pregnancy in SCA, increased maternal and fetal death, recurrent miscarriages, and the impact of pregnancy on the clinical
course of SCA. However, most of these reports were not confirmed by controlled trials.
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Table 1 – Clinical data at menopause of Brazilians with sickle cell disease (SCD) taking or not taking hydroxyurea (HU).

Total number of
patients (n = 15)
SCD/HU (n = 9)
SCD/No HU (n = 6)
Brazilians without
SCD (n = 456)

Age (years)a

VOCs/year Decreased
pain intensity

Hot flashes Insomnia Depression Anxiety Vaginal
dryness

Decreased
libido

46.4 ± 4.87

Decreased

12

12

11

5

9

8

9

44.4 ± 4.88
49.3 ± 3.33
51.2 ± 5.0

Decreased
Decreased
N/A

7
5
N/A

6
6
N/A

8
3
N/A

3
2
N/A

7
2
N/A

5
3
N/A

4
5
N/A

HU: hydroxyurea; n: number; N/A: not applicable; NS: not significant; VOCs: vaso-occlusive crises.
a

Mean ± standard deviation calculated by basic statistics using Systat 13.

Women with SCA require special attention for the many
obstetric and gynecologic issues associated with this complex disease. All aspects of female life from menarche through
menopause are based primarily on observational, anecdotal,
retrospective, or cohort studies that may not reflect current
aspects of obstetric care.1
Growth and development of children with SCA are
impaired. Manifestations of growth failure include delayed
skeletal maturation, deficits in weight and height, delayed
pubertal development, delayed menarche, and delayed first
pregnancy. The mean age at menarche in healthy control subjects is significantly earlier than in SCA.1 Because of this, we
thought that menopause may be similarly delayed in women
with SCA. We were surprised to find that the opposite is true.
Although puberty and menarche are delayed in patients
with SCD, normal sexual maturation is attained by the majority of patients later in life, suggesting that these delays are due
to constitutional rather than primary endocrinologic factors.1
Reports specifically addressing menopause in SCD are very
few in the English literature.
One study mentions that 13 postmenopausal patients were
among the patients enrolled in a bone mass density study,
but no specific details about these patients were described.
The study found no correlation between bone mass density
and age, sex, or menopause.5 A recent review indicated that
premature menopause is a risk factor for infertility in women
with SCD.6
Little is known about menopause in patients with SCA. The
main reason is that the median life expectancy of women
with SCA is about 48 years.2 Because of this, both patients
and providers did not worry about menopause in women with
SCA. This is changing as the life expectancy of patients with
SCD is increasing gradually.
We must emphasize that the number of patients described
in this study is too small to make definitive conclusions. Nevertheless, it may suggest the presence of certain trends. Thus,
menopause seems to be associated with decreased frequency
of vaso-occlusive crises (VOCs) and decreased pain severity.
This salutary effect, however, seems to be counterbalanced by
the relative increase in insomnia, anxiety and depression.
Since the onset of menarche in patients with SCA is delayed
as mentioned above,1 one would expect that menopause may
be delayed as well. This does not seem to be the case. The
mean age of menopause in Brazilian women in the general population is 51.2 years.7 This study shows the mean
age of menopause of women with SCD is less than 51.2

years (Table 1). In addition, the mean age of menopause in
women taking HU tends to be even lower than that of women
not taking HU (44.4 vs 49.3, p = 0.03 using the t score test).
This is consistent with the finding that HU decreases the
Anti-Müllerian hormone (AMH) in women with SCA which,
in turn, decreases the ovarian reserve associated with early
menopause.8,9
The AMH is a serum marker of ovarian reserve9 and is a
predictor of the time of menopause.10 Women with SCD have
decreased levels of AMH9 and HU decreases it further.8 This
study suggests HU is associated with menopause at an earlier
age in SCA than in those not on HU.
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Appendix A. Supplementary data
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